This page shows the latest Cx601 news and features for those working in and with pharma, biotech and healthcare.
Alofisel - previously Cx601 - is approved to treat complex perianal fistulas in adult patients with nonactive or mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at
CX601 has been classed as an orphan treatment for treating people who don’t respond to drug therapy. ... offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”.
Takeda paid 25m upfront for rights to Cx601 for this indication outside the US, pledging another 355m in milestone payments, including 15m on approval by the EMA. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for
The drug - currently known as Cx601 - could potentially treat ‘complex’ perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... Meanwhile, TiGenix and partner Takeda has
In ADMIRE-CD, 56% of patients treated with Cx601 and usual supportive care went into remission, compared to 39% of patients who received placebo plus standard care. ... Existing therapies are limited and associated with complications and a high failure
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
authorisation for Cx601, so it was probably a good time for Takeda to make a move. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally administered for treatment of
Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...